Infectious diseases are becoming increasingly difficult to manage. While much healthcare effort is devoted to preventing the spread of disease and associated treatments, less attention is paid to the impact these infections have on the broader healthcare landscape, particularly on laboratories.
It is critically important that laboratories are equipped to handle sudden surges in demand in worst-case scenarios, such as pandemics. However, gaining support for investments in preventative measures has been a historic challenge. Appropriately, the broad socioeconomic impact of the SARS-CoV-2 pandemic sparked the need for a change in preparedness and investment mindset.
The availability of flexible molecular systems and serology solutions, a broad menu of high-quality IVD and open channel assays, a reliable global supply chain, and expert support can position laboratories for success in addressing current and future infectious disease management, while enabling the scalability to react in an outbreak situation.